Cargando…
Tumor immunosurveillance in human cancers
Until now, the anatomic extent of tumor (TNM classification) has been by far the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044219/ https://www.ncbi.nlm.nih.gov/pubmed/21249426 http://dx.doi.org/10.1007/s10555-011-9270-7 |
_version_ | 1782198699997265920 |
---|---|
author | Mlecnik, Bernhard Bindea, Gabriela Pagès, Franck Galon, Jérôme |
author_facet | Mlecnik, Bernhard Bindea, Gabriela Pagès, Franck Galon, Jérôme |
author_sort | Mlecnik, Bernhard |
collection | PubMed |
description | Until now, the anatomic extent of tumor (TNM classification) has been by far the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients’ disease-free and overall survival. Tumoral and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. The density and the immune cell location within the tumor have a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host-immune reaction. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice. |
format | Text |
id | pubmed-3044219 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-30442192011-04-04 Tumor immunosurveillance in human cancers Mlecnik, Bernhard Bindea, Gabriela Pagès, Franck Galon, Jérôme Cancer Metastasis Rev Article Until now, the anatomic extent of tumor (TNM classification) has been by far the most important factor to predict the prognosis of colorectal cancer patients. However, in recent years, data collected from large cohorts of human cancers demonstrated that the immune contexture of the primary tumors is an essential prognostic factor for patients’ disease-free and overall survival. Tumoral and immunological markers predicted by systems biology methods are involved in the shaping of an efficient immune reaction and can serve as targets for novel therapeutic approaches. Global analysis of tumor microenvironment showed that the nature, the functional orientation, the density, and the location of adaptive immune cells within distinct tumor regions influence the risk of relapse events. The density and the immune cell location within the tumor have a prognostic value that is superior to the TNM classification, and tumor invasion is statistically dependent on the host-immune reaction. Thus, the strength of the immune reaction could advance our understanding of cancer evolution and have important consequences in clinical practice. Springer US 2011-01-21 2011 /pmc/articles/PMC3044219/ /pubmed/21249426 http://dx.doi.org/10.1007/s10555-011-9270-7 Text en © The Author(s) 2011 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Article Mlecnik, Bernhard Bindea, Gabriela Pagès, Franck Galon, Jérôme Tumor immunosurveillance in human cancers |
title | Tumor immunosurveillance in human cancers |
title_full | Tumor immunosurveillance in human cancers |
title_fullStr | Tumor immunosurveillance in human cancers |
title_full_unstemmed | Tumor immunosurveillance in human cancers |
title_short | Tumor immunosurveillance in human cancers |
title_sort | tumor immunosurveillance in human cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044219/ https://www.ncbi.nlm.nih.gov/pubmed/21249426 http://dx.doi.org/10.1007/s10555-011-9270-7 |
work_keys_str_mv | AT mlecnikbernhard tumorimmunosurveillanceinhumancancers AT bindeagabriela tumorimmunosurveillanceinhumancancers AT pagesfranck tumorimmunosurveillanceinhumancancers AT galonjerome tumorimmunosurveillanceinhumancancers |